Result of General Meeting and Total Voting Rights

RNS Number : 4288P

Tissue Regenix Group PLC

09 June 2020

 

Tissue Regenix Group plc

Result of General Meeting

and

Total voting rights

Leeds, 9 June 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix", the "Company" or the "Group"), is pleased to announced that at a General Meeting held earlier today, all Resolutions as set out in the Circular and Notice of General Meeting dated 22 May, were duly passed by shareholders. Defined terms referred to in this announcement have the meaning given in the Circular and Notice of General Meeting dated 22 May.

Application has been made for the 5,859,626,212 new Ordinary Shares issued pursuant to the recent fundraising (comprised of the 4,811,626,212 Placing Shares, 800,000,000 PrimaryBid Shares, 248,000,000 Subscription Shares and an additional 11,600,000 new Ordinary Shares issued pursuant to the Company's existing authorities), (together the "Fundraising Shares") to be admitted to trading on AIM. It is anticipated that trading will commence at 8am on 10 June 2020. 

Gareth Jones, Interim CEO, Tissue Regenix Group: "We are pleased to have received shareholder approval for this fundraise. This investment will allow us to implement our capacity expansion programme and support the development of the Group as we look to scale our operations to address additional market opportunities."

The results of the polls are set out below:

Resolution	Votes for	% of votes cast	Votes against	% of votes cast	Votes cast in total	Total votes cast as a % of issued share capital	Votes withheld
Authorise the Directors under section 551 of the Companies Act 2006 to allot the New Ordinary Shares	583,293,491	97.95	12,195,653	2.05	595,489,144	50.81	508,081
Authorise the Directors to subdivide the 1,171,971,322 Ordinary Shares of 0.5 pence in the capital of the Company into 1,171,971,322 Ordinary Shares of 0.1 pence and 1,171,971,322 Deferred Shares of 0.4 pence in the capital of the Company	583,293,491	97.95	12,195,653	2.05	595,489,144	50.81	508,081
Special resolution to amend the articles of association	583,293,491	97.95	12,195,653	2.05	595,489,144	50.81	508,081
Special resolution to authorise the Directors under section 570 of the Companies Act 2006, to allot the New Ordinary Shares pursuant to the Fundraising on a non-pre-emptive basis.	583,307,442	97.95	12,181,702	2.05	595,489,144	50.81	508,081

Total voting rights

Following admission of the Fundraising Shares the number of Ordinary Shares of 0.1 pence in issue and number of voting rights will be  7,031,597,534 . The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For more Information:

Tissue Regenix Group plc Caitlin Pearson, Head of Communications	Tel: [phone]
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Jonathan Senior / Alex Price / Ben Maddison	Tel:  [phone]
FTI Consulting  Simon Conway / Victoria Foster Mitchell / Mary Whittow	Tel: [phone]

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL^®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies^®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

 

END

 

 

ROMEAAKNEEEEEFA